Pitfalls of Amyloid-Beta PET: Comparisons With 18 F-MK-6240 and 18 F-THK5351 PET

Clin Nucl Med. 2024 Apr 1;49(4):319-321. doi: 10.1097/RLU.0000000000005097. Epub 2024 Feb 6.

Abstract

We present 3 patients as pitfalls of amyloid-beta (Aβ) PET, who underwent 11 C-PiB (Aβ), 18 F-MK-6240 (Alzheimer disease [AD]-tau), and 18 F-THK5351 (astrogliosis) PET examinations. Despite negligible or tiny Aβ pathology, patients 1 and 2 were diagnosed with AD as the cause of symptoms. Despite widespread Aβ pathology, patient 3 was not diagnosed with AD as the cause of symptoms. However, if we had only conducted Aβ PET, patients 1 and 2 might not have been diagnosed with AD, whereas patient 3 might have been diagnosed with AD. Hence, both Aβ and AD-tau assessments are necessary to relate clinical symptoms to AD pathology.

MeSH terms

  • Alzheimer Disease* / diagnostic imaging
  • Aminopyridines
  • Amyloid beta-Peptides*
  • Humans
  • Isoquinolines*
  • Quinolines*

Substances

  • MK-6240
  • THK5351
  • Amyloid beta-Peptides
  • Aminopyridines
  • Isoquinolines
  • Quinolines